Ruxolitinib Plus Nivolumab in Patients with R/R Hodgkin Lymphoma after Failure of Check-Point Inhibitors: Preliminary Report on Safety and EfficacyVeronika Bachanová, Vaishalee P. Kenkre, Sabarish Ayyappan et al.|Blood|2021Cited by 14